Patient P-02102

Synthetic patientMETA-24 · Day 90 · 55–64 · F · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

56%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 65 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 78 GI-04 recommended — GI Support Protocol GI-04
Day 79 Patient accepted — Started GI-04 in the companion
Day 87 GI symptom burden −36% vs expected — GI Support Protocol GI-04
Day 93 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 65.

Primary contributors, last 14 days

Nutritional resilience-12
GI instability+7
Treatment adherence+7
Inflammatory activity+6
Toxicity+5

What helped?

GI Support Protocol GI-04Day 78
Result: symptom burden −36%

LIFE OS recommendation

Hydration Protocol HY-01

54%

probability of meaningful tolerance improvement

284 similar trajectories
70% showed improvement
median effect visible after 4 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
- WearableSleep 5.4 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
Inflammatory signalling ↑40
- BloodInflammatory load index 51
- WearableHRV 22 ms, trending down

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.3 · butyrate capacity 23/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 23 ms
Sleep: 5.8 h
Steps: 4,396
Resting HR: 79 bpm

Daily log: GI score 54, nutritional resilience 40, adherence 94.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02115	43%	S14	GI-04	improved	75
P-02575	38%	S14	ME-01	improved	73
P-02298	35%	S14	GI-04	improved	65
P-02309	34%	S09	—	—	67
P-02318	34%	S14	GI-04	no change	62
P-02060	33%	S14	GI-04	improved	54
P-02252	32%	S02	—	—	65
P-02666	31%	S14	ME-01	improved	51
P-02011	30%	S09	—	—	62
P-02099	30%	S15	—	—	61
P-02181	30%	S14	—	—	61
P-02197	30%	S12	—	—	60